Keywords: avidex, sees, positive, data, rhudex, trials, uk-based
Avidex sees positive data from RhuDex trials
Article | 20 March 2006
UK-based biopharmaceutical company Avidex says that its lead product candidate RhuDex, its orally-bioactive small-molecule CD80 antagonist, has successfully completed two ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
